Table 1. Clinical and Demographic Characteristics of Patients With HIV, HIV-HCV, and HCV-Infections a,b,c.
| HIV (n = 98) | HIV−HCV (n = 70) | HCV (n = 186) | P Value | |
|---|---|---|---|---|
| Male, No. (%) | 67 (68.4) | 46 (65.7) | 116 (62.4) | 0.591 b |
| Age, y, median (Q1−Q3) | 46 (38−54) | 48 (43−50) | 45 (37−58) | 0.845 a |
| BMI, kg/m2, median (Q1−Q3) | 24.8 (22.0−26.6) | 24.0 (21.0−26.0) | 24.0 (22.0−27.0) | 0.255 a |
| Race, No. (%) | ||||
| White | 90 (91.8) | 68 (97.1) | 182 (98.4) | 0.007 b |
| Asian | 0 (0) | 0 (0) | 2 (1.1) | |
| Black | 8 (8.2) | 2 (2.9) | 1 (0.5) | |
| Risk factors, No. (%) | ||||
| Homosexual | 79 (80.6) | 9 (12.9) | 3 (1.6) | < 0.001 b |
| Heterosexual | 16 (16.3) | 2 (2.9) | 0 (0) | |
| IDU | 3 (3.1) | 56 (80) | 89 (47.8) | |
| Other | 0 (0) | 3 (4.3) | 94 (50.5) | |
| Ethanol consumption, > 50 g/d, No. (%) | 7 (7.1) | 7 (10) | 28 (15.1) | 0.127 b |
| Smokers, No. (%) | 38 (38.8) | 54 (77.1) | 74 (39.8) | < 0.001 b |
| PLT, x 103/ml, median (Q1−Q3) | 212 (182.5−246) | 181 (134.5−232.7) | 193 (156.5−234) | 0.001 a |
| ALT, IU/mL | 25.5 (20.2−34) | 56 (37.5−76) | 58 (32−104) | < 0.001 a |
| HIV vs. HIV−HCV c | HIV vs. HCV c | |||
| AST, IU/mL | 24 (19−28) | 48 (32−65.5) | 44 (28−73) | < 0.001 a |
| HIV vs. HIV−HCV c | HIV vs. HCV c | |||
| GGT, IU/mL | 33.5 (19−49) | 95 (35.2−141.5) | 34.5 (20−81.5) | < 0.001 a |
| HIV vs. HIV−HCV c | HIV−HCV vs. HCV c | |||
| Total cholesterol, mg/dL | 199 (181−228) | 163.5 (133.8−184.8) | 177 (151.5−201.5) | < 0.001 a |
| HIV vs. HIV−HCV c | HIV vs. HCV c | |||
| HDL cholesterol, mg/dL | 46 (39−56.7) | 43 (33.5−53) | 51 (40−66) | 0.001 a |
| HIV−HCV vs. HCV c | ||||
| LDL cholesterol, mg/dL | 117.5 (102−147.8) | 91.5 (68−117) | 109 (93−133.5) | < 0.001 a |
| HIV vs. HIV−HCV c | ||||
| Glycaemia, mg/dL | 87.5 (81−95) | 88.5 (82.2−97.7) | 90 (81−100) | 0.541 a |
| Triglycerides, mg/dL | 127.5 (84.2−209) | 110.5 (77−171) | 84 (68−114) | < 0.001 a |
| HIV vs. HCVc;HIV−HCV vs. HCV c | ||||
| Lipodystrophy, No. (%) | 14 (14.3) | 26 (37.1) | 0 (0) | < 0.001 b |
| Years of known HIV infection, median (Q1−Q3) | 9 (3.2−12.0) | 21 (16.2−23.0) | − | < 0.001 a |
| CDC clinical stage, No. (%) | ||||
| A | 47 (48) | 17 (24.3) | − | 0.006 b |
| B | 28 (28.6) | 33 (47.1) | − | |
| C | 23 (23.5) | 20 (28.6) | − | |
| Patients with undetectable HIV load, No. (%) | 73 (74.5) | 52 (74.3) | − | 0.881 b |
| Current HIV load (only for those with detectable viral load, copies/mL), median (Q1−Q3) | 573 (64−9963) | 318 (80−8355.5) | − | 0.990 a |
| Nadir CD4⁺T−cell, median (Q1−Q3) | 244.5 (133−335.5) | 224.5 (111.8−334.0) | − | 0.395 a |
| Zenith HIV RNA, median (Q1−Q3) | 90265 (21370−213511) | 37424 (15129−100000) | − | 0.022 a |
| Current CD4⁺T−cell, median (Q1−Q3) | 593.5 (428.2−794) | 547.5 (347.0−805.0) | − | 0.249 a |
| Patients receiving cART, No. (%) | 91 (92.9) | 68 (97.1) | − | 0.385 b |
| Months of cART, median (Q1−Q3) | 80.5 (26−144) | 145 (62.5−213.8) | − | < 0.001 a |
| HCV genotype, No. (%) | ||||
| 1 | − | 33 (47.1) | 91 (48.9) | 0.035 b |
| 2 | − | 1 (1.4) | 23 (12.4) | |
| 3 | − | 20 (28.6) | 46 (24.7) | |
| 4 | − | 6 (8.6) | 8 (4.3) | |
| Years of known HCV infection, median (Q1−Q3) | − | 16.5 (12.2−19.7) | 4 (1−12) | < 0.001 a |
| HCV load UI/mL, median (Q1−Q3) | − | 1332995 (471786−2561296) | 581294 (116124−2058326) | 0.004 a |
a Kruskal-Wallis test.
b Chi-Square test.
c P < 0.01.